P-R Herzig & Co Decreased Its Bristol Myers Squibb Co (BMY) Holding; Investors Real Estate Trust (IRET) Sentiment Is 1.18

June 18, 2018 - By Adrian Erickson

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Investors Real Estate Trust (IRET) investors sentiment decreased to 1.18 in 2018 Q1. It’s down -0.34, from 1.52 in 2017Q4. The ratio has dropped, as 66 active investment managers opened new and increased positions, while 56 cut down and sold their equity positions in Investors Real Estate Trust. The active investment managers in our database now have: 61.91 million shares, up from 61.84 million shares in 2017Q4. Also, the number of active investment managers holding Investors Real Estate Trust in top ten positions was flat from 0 to 0 for the same number . Sold All: 12 Reduced: 44 Increased: 44 New Position: 22.

P-R Herzig & Co decreased Bristol Myers Squibb Co (BMY) stake by 20.5% reported in 2018Q1 SEC filing. P-R Herzig & Co sold 6,899 shares as Bristol Myers Squibb Co (BMY)’s stock declined 23.11%. The P-R Herzig & Co holds 26,749 shares with $1.69M value, down from 33,648 last quarter. Bristol Myers Squibb Co now has $87.72B valuation. The stock decreased 2.07% or $1.135 during the last trading session, reaching $53.665. About 4.79M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 2.98% since June 18, 2017 and is downtrending. It has underperformed by 15.55% the S&P500. Some Historical BMY News: ; 23/05/2018 – Merck’s KEYTRUDA┬« (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line; 16/04/2018 – So now embargo times may be shifting $BMY; 27/03/2018 – BRISTOL-MYERS: FDA ACCEPTS APPLICATION FOR OPDIVO PLUS YERVOY; 26/04/2018 – Bristol-Myers 1Q Gross Margin 69.5%; 07/05/2018 – Roche: FDA Grants Priority Review for Tecentriq in Lung Cancer Treatment; 13/04/2018 – Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly; 16/04/2018 – Bristol-Myers: In Phase 3 CheckMate -214 Clinical Trial, Opdivo + Yervoy Combination Demonstrated a Significant and Unprecedented Increase in Overall Survival; 26/04/2018 – BRISTOL-MYERS SQUIBB CO – U.S. REVENUES INCREASED 1% TO $2.8 BILLION IN THE QUARTER COMPARED TO THE SAME PERIOD A YEAR AGO; 16/04/2018 – OPDIVO 1-YEAR PROGRESSION-FREE SURVIVAL RATE `SUPERIOR BENEFIT’; 25/05/2018 – IMFINZI(R) (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer

Investors sentiment decreased to 0.83 in Q1 2018. Its down 0.11, from 0.94 in 2017Q4. It is negative, as 64 investors sold BMY shares while 573 reduced holdings. 111 funds opened positions while 418 raised stakes. 1.12 billion shares or 1.08% more from 1.11 billion shares in 2017Q4 were reported. 1.19M were reported by Raymond James Associates. 222,823 are held by Amalgamated Savings Bank. Moreover, Canal has 4.33% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 195,000 shares. Vanguard Grp Inc Inc reported 0.35% stake. Saybrook Nc holds 0.46% in Bristol-Myers Squibb Company (NYSE:BMY) or 15,238 shares. Birmingham Capital Al stated it has 67,573 shares. Quantres Asset Mgmt Limited holds 0.3% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 7,900 shares. 16,139 were reported by Sheets Smith Wealth Mngmt. Ontario – Canada-based Canada Pension Plan Inv Board has invested 0.57% in Bristol-Myers Squibb Company (NYSE:BMY). Raymond James Na invested 0.36% in Bristol-Myers Squibb Company (NYSE:BMY). 113,957 are held by Sumitomo Mitsui Asset. Willis Inv Counsel holds 0.82% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 168,366 shares. Dynamic Advisor Solutions Limited Liability Corporation owns 20,447 shares for 0.33% of their portfolio. 10,353 were reported by Hollencrest Capital Mngmt. Kentucky-based D Scott Neal has invested 0% in Bristol-Myers Squibb Company (NYSE:BMY).

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 2 Sell and 14 Hold. Therefore 27% are positive. Bristol-Myers Squibb Company had 87 analyst reports since July 28, 2015 according to SRatingsIntel. Jefferies maintained it with “Hold” rating and $78 target in Tuesday, June 14 report. The stock has “Hold” rating by Jefferies on Thursday, November 16. Piper Jaffray maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, September 22 with “Hold” rating. The firm earned “Hold” rating on Friday, March 23 by Jefferies. The rating was maintained by Citigroup with “Buy” on Wednesday, October 18. The rating was maintained by Citigroup on Wednesday, October 25 with “Buy”. The stock has “Sell” rating by BMO Capital Markets on Monday, June 5. SunTrust upgraded the stock to “Buy” rating in Monday, October 30 report. The rating was initiated by Societe Generale with “Sell” on Wednesday, April 6. BMO Capital Markets downgraded the shares of BMY in report on Monday, January 25 to “Market Perform” rating.

Since April 30, 2018, it had 1 insider purchase, and 0 sales for $249,948 activity. On Monday, April 30 the insider Paliwal Dinesh C bought $249,948.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Bristol-Myers Top NASH Contenders” on June 12, 2018, also Seekingalpha.com with their article: “Merck up 2% premarket on positive Keytruda data; Bristol-Myers down 2%” published on June 04, 2018, Seekingalpha.com published: “Bristol-Myers Squibb (BMY) Presents at UBS Global Healthcare Conference (Transcript)” on May 22, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Neon Therapeutics readies IPO” published on June 01, 2018 as well as Streetinsider.com‘s news article titled: “Bristol-Myers Squibb (BMY) Says China National Drug Administration Approved Country’s First Immuno-Oncology …” with publication date: June 15, 2018.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on July, 26. They expect $0.87 earnings per share, up 17.57% or $0.13 from last year’s $0.74 per share. BMY’s profit will be $1.42B for 15.42 P/E if the $0.87 EPS becomes a reality. After $0.94 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -7.45% negative EPS growth.

Analysts await Investors Real Estate Trust (NYSE:IRET) to report earnings on June, 27. They expect $0.09 earnings per share, down 18.18% or $0.02 from last year’s $0.11 per share. IRET’s profit will be $12.08M for 16.11 P/E if the $0.09 EPS becomes a reality. After $0.09 actual earnings per share reported by Investors Real Estate Trust for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Since January 1, 0001, it had 11 buys, and 0 insider sales for $570,468 activity.

Pacific Heights Asset Management Llc holds 1.38% of its portfolio in Investors Real Estate Trust for 2.50 million shares. Endeavour Capital Advisors Inc owns 1.45 million shares or 1.23% of their US portfolio. Moreover, Grace & White Inc Ny has 1.15% invested in the company for 1.08 million shares. The Minnesota-based Bremer Trust National Association has invested 0.15% in the stock. Gsa Capital Partners Llp, a United Kingdom-based fund reported 445,092 shares.

Investors Real Estate Trust is a real estate investment trust. The company has market cap of $778.55 million. The trust invests in real estate markets of United States. It has a 4.5 P/E ratio. It is primarily engaged in investment and operation of the the real estate assets.

The stock increased 1.58% or $0.09 during the last trading session, reaching $5.8. About 209,169 shares traded. Investors Real Estate Trust (IRET) has declined 11.00% since June 18, 2017 and is downtrending. It has underperformed by 23.57% the S&P500. Some Historical IRET News: ; 12/03/2018 – Investors Real Estate Tr 3Q EPS $1.12; 22/03/2018 – IRET Adds Two Vice Presidents of Operations; 12/03/2018 – INVESTORS REAL ESTATE TRUST – QTRLY CORE FFO PER SHARE $0.09; 12/03/2018 – INVESTORS REAL ESTATE TRUST – QUARTERLY SAME-STORE NOI GROWTH OF 5.8% OVER SAME PERIOD IN PRIOR YEAR; 13/03/2018 – IRET Debt Risk Falls 3 Levels in Bloomberg Model; 28/03/2018 – IRET Acquires 390-Home Multifamily Property in Denver for $128.7 Million; 05/03/2018 IRET Announces Distributions for the Fourth Quarter of Fiscal Year 2018; 12/03/2018 – Investors Real Estate Tr 3Q FFO 4c/Shr; 12/03/2018 – INVESTORS REAL ESTATE TRUST – QTRLY FFO PER SHARE $0.04; 12/03/2018 – INVESTORS REAL ESTATE 3Q FFO/SHR 4C, EST. 10C

Investors Real Estate Trust (NYSE:IRET) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>